Rein Therapeutics Inc. (RNTX)

NASDAQ: RNTX · Real-Time Price · USD
1.250
+0.120 (10.62%)
Aug 22, 2025, 4:00 PM - Market closed
10.62%
Market Cap29.83M
Revenue (ttm)n/a
Net Income (ttm)-59.15M
Shares Out 23.31M
EPS (ttm)-2.64
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume39,878
Open1.130
Previous Close1.130
Day's Range1.110 - 1.300
52-Week Range1.040 - 4.400
Beta1.31
AnalystsHold
Price Targetn/a
Earnings DateAug 14, 2025

About RNTX

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes preclinical programs... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 11
Stock Exchange NASDAQ
Ticker Symbol RNTX
Full Company Profile

Financial Performance

Financial Statements

News

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet med...

3 days ago - GlobeNewsWire

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant un...

7 days ago - GlobeNewsWire

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Meeting adjourned to Wednesday, July 23, 2025 at 9:00 a.m. Eastern Time AUSTIN, Texas , June 24, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a...

2 months ago - PRNewsWire

US FDA puts on hold Rein Therapeutics' lung disease drug trial

Rein Therapeutics has paused patient enrollment and dosing in a mid-stage trial of its lung disease drug in the U.S. after the Food and Drug Administration placed a clinical hold, the drug developer s...

2 months ago - Reuters

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026 AUSTIN, Texas , May 27, 2025 /P...

Other symbols: IQV
3 months ago - PRNewsWire

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

Presentations further support the dual mechanism of LTI-03 and the development of Cav1-related peptides for the treatment of idiopathic pulmonary fibrosis (IPF) Company recently initiated RENEW Phase ...

3 months ago - PRNewsWire

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

RENEW Phase 2 trial evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) initiated with topline interim data expected in the first half of 2026 Two abstra...

3 months ago - PRNewsWire

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

The RENEW Phase 2 trial will enroll up to 120 IPF patients with topline data expected in the first half of 2026 In the previously reported Phase 1b study, LTI-03 showed a positive trend in seven out o...

3 months ago - PRNewsWire

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

AUSTIN, Texas , May 1, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet m...

4 months ago - PRNewsWire

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

AUSTIN, Texas , April 30, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unme...

4 months ago - PRNewsWire

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

AUSTIN, Texas , April 28, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unme...

4 months ago - PRNewsWire

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

AUSTIN, Texas , April 23, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unme...

4 months ago - PRNewsWire

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Manuscript highlights the effects of caveolin scaffolding domain peptide LTI-2355 on myeloid cell activity in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F) AUS...

4 months ago - PRNewsWire

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF) in the first half of 2025 Positive topli...

4 months ago - PRNewsWire